Symrise AG hit its target goal—EBITDA margin of 20 percent—in Fiscal Year 2011 with its Scent & Care division reporting sales of €801.4 million, with plans to increase to put the new menthol plant in Holzminden into operation over the course of the year. ...More
On Wednesday of last week, I had the opportunity to visit Symrise’s Park Ave. creative theater that’s responsible for predicting consumer-based, global fragrance trends. Unlike fads that come and go (think vampires), these trends set the stage for the next several years and ...More
Symrise and Cutech jointly developed an ex vivo real skin model that provides conclusive information on the efficacy of, for example, anti-aging products, bridging the gap between in vitro and in vivo testing. ...More
Symrise won two BSB awards. SymFinity® 1298 won a first price for its anti-aging properties. A second place went to SymPeptide® 226EL for its eyelash-growing effect. ...More
Symrise has been a regular investor in Reed Sinopharm Exhibition’s (RSE) Personal Care and Homecare Ingredients (PCHi) exhibition and conference since 2008; and Symrise announced its going to increase its booth area by more than half for PCHi 2012. ...More
Symrise launched SymFinity® 1298, a concentrate of Echinacea purpurea (E. purpurea), shown to be effective in preventing long-term damage to the skin. ...More
SupplySide
